The yellowing of the skin in jaundice has made bilirubin notorious as a toxin. But at physiological concentrations, bilirubin functions as one of the body's most potent endogenous antioxidants — and your genome partly determines how much of it you carry. The rs2361502 variant in the MROH2A gene, situated directly adjacent to the UGT1A gene cluster¹¹ UGT1A gene cluster
A family of enzymes on chromosome 2q37.1 responsible for glucuronidating bilirubin — conjugating it so the liver can excrete it in bile on chromosome 2q37.1, is one of the genetic markers most consistently associated with circulating bilirubin concentrations in genome-wide association studies.

The Mechanism

rs2361502 is an intronic variant within MROH2A (maestro heat-like repeat family member 2A, also annotated as HEATR7B1), a gene whose protein product is poorly characterised at the functional level. The variant itself is unlikely to alter MROH2A protein function. Rather, because MROH2A sits immediately adjacent to the UGT1A locus, rs2361502 is a tag SNP²² tag SNP
A tag SNP is a marker variant in strong linkage disequilibrium with a functional variant; it tracks the functional variant across populations even though it has no effect itself that captures regulatory variation in UGT1A1 — specifically variation that modulates how efficiently the liver conjugates bilirubin for excretion. Carriers of the C allele have lower hepatic UGT1A1 activity in this region, resulting in slower bilirubin clearance and thus higher steady-state serum concentrations. Each copy of the C allele raises total serum bilirubin by roughly 0.096–0.098 mg/dL.

At physiological concentrations (0.2–1.2 mg/dL), bilirubin scavenges reactive oxygen species³³ reactive oxygen species
Unstable molecules such as superoxide, hydroxyl radical, and peroxynitrite produced during normal metabolism and during inflammation; excessive ROS damages DNA, lipids, and proteins and inhibits LDL oxidation, a key early step in atherosclerosis. It also suppresses the NADPH oxidase system and blunts inflammatory cytokine signalling.

The Evidence

The strongest direct evidence for rs2361502 comes from a genome-wide association study of 430 subjects with metabolic syndrome⁴⁴ genome-wide association study of 430 subjects with metabolic syndrome
Coltell O et al. Genome-Wide Association Study (GWAS) on Bilirubin Concentrations in Subjects with Metabolic Syndrome. Nutrients, 2019 drawn from the PREDIMED Plus-Valencia cohort. rs2361502 reached genome-wide significance (p=4×10⁻⁸), with each C allele increasing bilirubin by 0.096 mg/dL. A larger signal (p=7×10⁻²³, beta=0.098 mg/dL per C allele) emerged from the eMERGE network analysis by Bielinski et al., confirming the locus in a population with thousands of individuals. A PheWAS in HIV-positive individuals⁵⁵ PheWAS in HIV-positive individuals
Moore CB et al. Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis, 2015 from AIDS Clinical Trials Group protocols (n=2,547) independently replicated the bilirubin association (p=3×10⁻⁶).

The clinical significance of chronically elevated bilirubin is well-established. A meta-analysis of 16 observational studies in 175,911 participants⁶⁶ meta-analysis of 16 observational studies in 175,911 participants
Nano J et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes. Diabetes Metab, 2016 found those in the highest bilirubin tertile had roughly 30% lower odds of metabolic syndrome (OR 0.70, 95% CI 0.62–0.78) and 23% lower odds of type 2 diabetes (OR 0.77, 95% CI 0.67–0.87) compared to those with the lowest bilirubin. Similarly, both retrospective and prospective studies consistently show an inverse relationship between bilirubin and cardiovascular disease events, with individuals carrying UGT1A1*28 — the canonical low-clearance allele for which rs2361502 serves as a marker — having significantly lower CVD risk⁷⁷ significantly lower CVD risk
Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk. Atherosclerosis, 2008 than wild-type carriers.

It should be noted that Mendelian randomization has not yet confirmed a strong causal role for bilirubin in cardiovascular protection: a 2015 analysis using rs6742078 as an instrumental variable found OR 1.03 (95% CI 0.98–1.09) for coronary heart disease per SD increase in bilirubin, suggesting some of the observational benefit may reflect confounding. The protective signal is robust observationally but causal confirmation awaits larger MR studies.

Practical Actions

Carriers of the CC genotype maintain chronically higher bilirubin concentrations, which appear to confer modest metabolic protection. The main clinical value of knowing this genotype is interpreting blood test results accurately: mildly elevated bilirubin (up to ~2 mg/dL in the absence of symptoms) is a benign, genetically-driven phenotype rather than a sign of liver disease. Additionally, behaviours and substances that increase oxidative stress — smoking, very high alcohol intake, or chronic exposure to environmental oxidants — will consume bilirubin's antioxidant capacity, eroding the genetic advantage.

CT heterozygotes have intermediate bilirubin and a similar but attenuated benefit.

TT homozygotes have the reference (lower) bilirubin. This does not imply disease risk; average bilirubin concentrations are already within the protective range for most people. Maintaining low oxidative stress through diet rich in antioxidant micronutrients (vitamins C and E, polyphenols) partially compensates for the reduced endogenous bilirubin buffering.

Interactions

rs2361502 is in linkage disequilibrium with several UGT1A1 variants, including rs887829 and rs6742078, which are the canonical functional markers for Gilbert syndrome and the UGT1A1*28 promoter haplotype. Carriers of multiple C-raising alleles at this locus (e.g., rs2361502 CC combined with rs887829 minor-allele homozygosity) likely experience additive bilirubin elevation. No published compound-genotype analysis of rs2361502 combined with other UGT1A1 variants has been reported, but the biological logic of additive UGT1A1 suppression is well established.

Deep inside every monoaminergic synapse, an enormous scaffolding protein called Piccolo acts as the master organiser of neurotransmitter release. Piccolo¹¹ Piccolo
Encoded by PCLO, a presynaptic cytomatrix protein (~550 kDa) that anchors at the active zone and coordinates synaptic vesicle docking, priming, and endocytic recycling is particularly critical at serotonergic and dopaminergic synapses in limbic circuits relevant to mood regulation. The rs2522833 variant (p.Ser4814Ala) sits within Piccolo's C2A domain — a calcium-sensing module that governs how efficiently vesicles are made available for release — and the resulting amino acid substitution has been linked to altered HPA axis regulation, depression vulnerability, and modified response to antidepressant treatment.

The Mechanism

The C2A domain of Piccolo binds calcium with low affinity, acting as a sensor that modulates the readily releasable pool of synaptic vesicles during sustained neural firing. When serine at position 4814 is replaced by alanine, the local conformation of the C2A domain changes subtly — serine carries a hydroxyl group capable of hydrogen bonding that alanine lacks. Functional studies in mouse models carrying the Ser→Ala substitution found two cellular-level consequences: increased synaptic Piccolo protein levels and approximately 30% higher excitatory synaptic transmission in cultured neurons²² increased synaptic Piccolo protein levels and approximately 30% higher excitatory synaptic transmission in cultured neurons
Giniatullina et al. Neuroscience, 2015 (PMID 26045179). Calcium-dependent phospholipid binding and total vesicle pool size were unaffected. The net result at the human level is a presynaptic system with mildly altered monoamine release dynamics — likely expressed most clearly under demand conditions such as chronic stress, acute stressors, or pharmacological challenge rather than at rest.

The C allele (encoding Ala-4814) is the risk variant, while the A allele (encoding Ser-4814) represents the reference state. The PCLO gene lies on chromosome 7q11, and rs2522833 is on the minus strand; the plus-strand alleles reported in genome files are A (Ser, reference) and C (Ala, risk).

The Evidence

The genetic signal for PCLO and major depressive disorder has been replicated across multiple independent cohorts. The Rotterdam Study found rs2522833 associated with DSM-defined depressive disorders (P=0.0025) and achieved genome-wide significance (P=1.93×10⁻⁹) in meta-analysis across three population cohorts³³ found rs2522833 associated with DSM-defined depressive disorders (P=0.0025) and achieved genome-wide significance (P=1.93×10⁻⁹) in meta-analysis across three population cohorts
Hek et al. Human Molecular Genetics, 2010. A subsequent Dutch twin-registry study confirmed genome-wide significance at the PCLO locus (rs2715157, p=2.91×10⁻⁸; gene-level p=1.48×10⁻⁷) comparing 1,942 lifetime MDD cases against 4,565 controls⁴⁴ comparing 1,942 lifetime MDD cases against 4,565 controls
Mbarek et al. Twin Research and Human Genetics, 2017.

Two independent lines of evidence link rs2522833 specifically to HPA axis function. In 205 MDD inpatients treated with antidepressants over four weeks, C-allele carriers showed significantly greater reductions in cortisol and ACTH levels during treatment (p=0.01–0.02, η²=0.014–0.031) compared to AA carriers, whose HPA measures barely shifted⁵⁵ C-allele carriers showed significantly greater reductions in cortisol and ACTH levels during treatment (p=0.01–0.02, η²=0.014–0.031) compared to AA carriers, whose HPA measures barely shifted
Schuhmacher et al. IJNP, 2011. Clinical response (symptom scores) was similar across genotypes, suggesting that the HPA modulation is a biological signal independent of whether the treatment works subjectively. In healthy adults, a study of 66 young volunteers found C-allele carriers had a blunted cortisol awakening response (CAR AUCinc: 282 vs 467, p=0.042) and higher neuroticism scores compared to AA carriers⁶⁶ C-allele carriers had a blunted cortisol awakening response (CAR AUCinc: 282 vs 467, p=0.042) and higher neuroticism scores compared to AA carriers
Kuehner et al. Translational Psychiatry, 2011 — indicating that the HPA impact is present even without depression, suggesting it precedes rather than results from the disorder.

Structural brain imaging reinforced the picture. In drug-naive first-episode MDD patients, C-allele carriers showed significantly smaller left temporal pole gray matter volume (P=0.003) compared to healthy C-carrier controls, with elevated plasma cortisol (12.76±6.10 vs 9.31±3.60 nmol/L, P=0.045)⁷⁷ C-allele carriers showed significantly smaller left temporal pole gray matter volume (P=0.003) compared to healthy C-carrier controls, with elevated plasma cortisol (12.76±6.10 vs 9.31±3.60 nmol/L, P=0.045)
Igata et al. Translational Psychiatry, 2017. The left temporal pole is implicated in emotional memory, social cognition, and the interface between affect and cognition — all functions disrupted in depression. Personality studies further showed C-allele carriers score higher on Harm Avoidance and lower on Novelty Seeking⁸⁸ Harm Avoidance and lower on Novelty Seeking
Minelli et al. Journal of Affective Disorders, 2012 — a temperament configuration associated with fearfulness, fatigue, and reduced reward-seeking that predisposes to both depression and anxiety.

It is important to note that the PCLO association has not replicated in all large GWAS efforts. The variant's per-allele effect is modest and polygenic. The evidence is strongest for the HPA-axis phenotype and antidepressant response modulation; the direct depression risk signal is moderate rather than established.

Practical Actions

Because the C allele's main documented effects are on HPA axis reactivity and antidepressant treatment response, actionable strategies centre on supporting HPA regulation and optimising SSRI response monitoring. The blunted cortisol awakening response in C-carriers suggests that the hypothalamic-pituitary-adrenal circuit is already under-responding rather than over-responding — a pattern associated with burnout and emotional exhaustion rather than acute stress reactivity. Practices that support healthy HPA axis tone (robust awakening routines that reinforce the cortisol awakening response, phosphatidylserine supplementation to normalise HPA sensitivity) are relevant. For C-carriers undergoing SSRI or SNRI treatment, the Schuhmacher data suggests that HPA biomarkers (morning cortisol) change detectably during treatment — tracking this can provide an early biological signal of treatment engagement.

Interactions

The most clinically meaningful gene-gene interactions for rs2522833 are with other monoaminergic system variants. The serotonin transporter promoter polymorphism 5-HTTLPR (SLC6A4) and COMT rs4680 (Val158Met) both influence monoaminergic synaptic tone and have been studied alongside PCLO rs2522833 in antidepressant response contexts. Carriers of C-allele in PCLO combined with SLC6A4 s-allele (reduced serotonin reuptake capacity) represent a theoretically compounded serotonergic vulnerability. CREB1 rs4675690, another early MDD GWAS candidate linked to transcriptional regulation of monoamine pathways, represents an additional potential interaction partner. These combinations have not yet been studied in adequately powered samples and should be considered hypothesis-generating rather than established.

The heart's pumping power depends on the precise choreography of sarcomeric proteins — molecular motors that convert ATP into coordinated contraction. Beta-myosin heavy chain¹¹ Beta-myosin heavy chain
Encoded by MYH7; the dominant myosin isoform in adult ventricular cardiomyocytes, making up roughly 30% of total ventricular protein mass is the central force-generator of this system. rs267606908 replaces an aspartate at position 906 of this protein with a glycine — a conservative-looking swap that nonetheless disrupts the motor's kinetics profoundly. Carriers of the C allele face a substantially elevated risk of hypertrophic cardiomyopathy (HCM)²² hypertrophic cardiomyopathy (HCM)
A structural heart disease defined by unexplained left ventricular hypertrophy not caused by pressure overload; the most common inherited cardiac condition, affecting 1 in 500 people overall, and are at risk for sudden cardiac death and progressive heart failure.

The Mechanism

Beta-myosin works through a mechanochemical cycle: ATP binds to the motor domain, hydrolysis cocks the lever arm, actin binding triggers force release (the power stroke), and ADP dissociation resets the cycle. The Asp906 residue sits in a region critical for Switch-2 closure³³ Switch-2 closure
A structural movement within the myosin motor domain that gates the release of the hydrolysis products; defective Switch-2 closure slows the ATPase cycle and traps the motor in a force-producing state. Replacing Asp906 with glycine disrupts this geometry in two measurable ways: the motor's maximum ATPase rate drops ~30%, and the hydrolysis step itself is slowed 3-fold compared to wild-type.

Yet paradoxically, force production increases. Single-molecule laser trap experiments⁴⁴ Single-molecule laser trap experiments
Sommese et al. used optical tweezers to measure the force a single myosin molecule produces during its power stroke; the technique isolates individual motor events from the ensemble showed D906G myosin generates approximately 50% more force per power stroke (2.1 vs 1.4 piconewtons) than wild-type, and ensemble loaded-motility assays confirmed this hypercontractile phenotype. In muscle fiber studies, actin filaments translocated 34% faster over Asp906Gly myosin compared to wild-type. The result is a motor that generates excessive force while cycling inefficiently — a combination that imposes chronic mechanical stress on cardiomyocytes, activates pro-fibrotic signaling cascades, and drives pathological hypertrophy.

A 2024 transgenic pig model reproduced the human phenotype with high fidelity. Animals carrying the D906G mutation⁵⁵ D906G mutation
Modeled in the closely related MYH7 isoform of the pig heart developed ventricular fibrosis, cardiomyocyte loss, and activated TGF-β/Smad2/3, ERK1/2, and Nox4/ROS/NF-κB signaling — all pathways implicated in HCM progression and end-stage cardiac remodeling.

The Evidence

rs267606908 was reviewed and classified as pathogenic by the ClinGen Cardiomyopathy Variant Curation Expert Panel⁶⁶ ClinGen Cardiomyopathy Variant Curation Expert Panel
An NIH-funded consortium of cardiomyopathy genetics experts that systematically reviews variant evidence using standardized ACMG/AMP criteria in December 2016. With 18 independent ClinVar submissions all converging on "pathogenic" status, this is among the better-curated HCM variants in the genome.

Clinical penetrance data are sobering. A Chinese family study⁷⁷ Chinese family study
Wang et al. 2024, published in the Chinese Heart Journal, studying 5 unrelated probands and their families found 12 of 13 mutation carriers diagnosed with HCM, with 2 sudden cardiac deaths, 2 SCD-survival events, and 3 deaths before age 30 among the families. A earlier US biochemical study estimated penetrance at 25%⁸⁸ estimated penetrance at 25%
Alpert et al. 2005; penetrance varied from 25% for Asp906Gly to 46% for Leu908Val among family members examined, noting that "despite the low penetrance, hypertrophy was severe in several heterozygotes." This variability — 25-90% depending on the study population — reflects the influence of genetic modifiers, age at assessment, and environmental triggers on phenotypic expression.

At the severe end of the spectrum, a Japanese case series⁹⁹ Japanese case series
Naito et al. 2023, three patients with MYH7 R453 variants — the residue at protein position 453 in the older, alternative numbering that corresponds to Asp906 in current HGVS notation documented rapid progression from preserved ejection fraction to end-stage heart failure, requiring cardiac resynchronization defibrillators, left ventricular assist devices, and transplant listing. Histopathology showed cardiomyocyte disarray and interstitial fibrosis — the classic end-organ signature of HCM progression.

Practical Implications

The central action for any carrier of the C allele is cardiac surveillance: periodic echocardiograms and ECGs, ideally under the care of a cardiomyopathy specialist. The goal is early detection of hypertrophy, outflow tract obstruction, and arrhythmia — all three of which are more manageable when caught before symptoms develop. Competitive sport carries elevated sudden death risk for HCM carriers and requires a specialist evaluation before participation.

Pharmacological options for symptomatic HCM now include myosin inhibitors (mavacamten, aficamten) — drugs designed precisely to counteract the hypercontractile state that MYH7 pathogenic variants produce. These are prescription medications requiring specialist management but represent a mechanism-matched intervention for this class of variant. Beta-blockers and calcium channel blockers remain first-line agents for symptom control and rate management in HCM with obstruction.

Cascade genetic testing in first-degree family members is standard of care. Each child, sibling, or parent of a confirmed carrier has a 50% chance of carrying the same variant; early identification in asymptomatic relatives allows prophylactic monitoring before structural disease develops.

Interactions

HCM phenotype severity from MYH7 pathogenic variants is modified by sarcomeric modifier variants elsewhere in the genome — particularly in genes encoding titin (TTN)¹⁰¹⁰ titin (TTN)
The largest human protein, functioning as the sarcomere's molecular spring and ruler; rare TTN variants can act as independent HCM or DCM causes, alpha-tropomyosin (TPM1, rs117022535), and myosin-binding protein C (MYBPC3). Compound heterozygosity — carrying pathogenic variants in two sarcomeric genes simultaneously — is associated with earlier onset and more severe disease than single-gene HCM. The related variant rs121913625 (MYH7 R453C, Arg453Cys) is a distinct pathogenic HCM mutation at a different residue in the same gene with overlapping but not identical biochemical consequences.

Familial Mediterranean fever (FMF) is an autoinflammatory disease defined by episodic, self-limiting attacks of fever and serositis — sterile inflammation of the abdominal, pleural, or pericardial lining — lasting 12 to 72 hours, then abruptly resolving. Between attacks, most patients feel well. The gene responsible, MEFV, encodes pyrin¹¹ pyrin
a scaffolding protein that assembles the pyrin inflammasome and controls release of IL-1β, the master cytokine of innate immunity. When pathogenic variants impair pyrin's regulatory capacity, inflammasome activation becomes constitutive, triggering unprovoked inflammatory attacks.

V726A (p.Val726Ala, c.2177T>C) is one of five founder mutations²² founder mutations
mutations that arose in a common ancestral population and were then spread as the population migrated; founder mutations are highly enriched in specific ethnic groups that together account for approximately 74% of FMF chromosomes across Armenians, Arabs, Turks, and Sephardic Jews. It sits in exon 10, the hotspot for severe FMF mutations, alongside M694V and M680I. Unlike E148Q (exon 2, which is debated), V726A is unambiguously pathogenic: ClinVar classifies it Pathogenic/Likely pathogenic across 43 of 56 independent submissions with no conflicts.

The Mechanism

Valine at position 726 sits within the B30.2 (SPRY) domain³³ B30.2 (SPRY) domain
the C-terminal regulatory domain of pyrin that senses RhoA GTPase effector signals and microbial toxins, gating inflammasome activation of pyrin. This domain normally maintains pyrin in an autoinhibited, inactive state through interactions with regulatory kinases PKN1 and PKN2. Substituting valine with the smaller, non-polar alanine at position 726 disrupts a stabilizing contact within the B30.2 fold. The result is decreased PKN1/14-3-3 binding and constitutive activation of the pyrin inflammasome — spontaneous caspase-1 cleavage of pro-IL-1β and pro-IL-18, without the microbial trigger normally required.

The severity of this dysfunction is intermediate. Functional studies show V726A pyrin retains more residual regulatory capacity than M694V — quantified as a higher threshold for spontaneous activation. This mechanistic gradient maps directly onto clinical observations: V726A homozygotes have more manageable disease than M694V homozygotes, and respond better to colchicine prophylaxis.

The Evidence

Genotype-phenotype correlation studies across multiple populations consistently rank V726A as intermediate severity. In a cohort of Arab FMF patients, Majeed et al. (2002)⁴⁴ Majeed et al. (2002) documented a mean severity score of 10±3 for V726A/V726A homozygotes versus 14±2 for M694V/M694V (p=0.003), placing V726A clearly below M694V but above M694I (score 6±1). Crucially, the compound heterozygous M694V/V726A genotype was associated with a severe clinical course, indicating that the severity ranking is genotype-specific rather than intrinsic to V726A alone.

Colchicine response data from Lidar et al. (2012)⁵⁵ Lidar et al. (2012) precisely quantifies the treatment gap between genotypes: V726A homozygotes achieved near-complete attack control (mean 0.08±0.20 attacks/year) on modest colchicine doses (1.13±0.41 mg/day), while M694V homozygotes remained partially active (0.70±1.06 attacks/year) despite requiring 1.98 mg/day, with 40% experiencing dose-limiting side effects. This places V726A homozygotes among the most colchicine-responsive MEFV genotypes.

Amyloidosis risk — the most feared long-term complication of FMF — correlates primarily with M694V genotype and duration of inadequately treated inflammation. V726A carriers have substantially lower amyloidosis rates: the largest pediatric cohort study (Öztürk et al. 2022⁶⁶ Öztürk et al. 2022, n=3,454) recorded only 0.3% secondary amyloidosis prevalence across all genotypes in the colchicine era, and the authors attribute this primarily to tight control in M694V-dominant cases. Heterozygous V726A carriers who are clinically asymptomatic are not at elevated amyloidosis risk.

A 30-year retrospective analysis of genotype-phenotype trends (Yildirim et al. 2025⁷⁷ Yildirim et al. 2025) confirmed that V726A was negatively correlated with severe PRAS (physician rating score) across the study period, reinforcing its classification as a milder exon 10 allele compared to M694V.

Practical Implications

For heterozygous carriers with no symptoms, V726A heterozygosity requires no treatment. FMF is autosomal recessive — a single pathogenic allele is generally insufficient to cause full disease. The carrier state may predispose to subclinical inflammation (elevated SAA or CRP between attacks) in some individuals, but this does not meet the threshold for prophylactic colchicine in asymptomatic adults.

For homozygous V726A carriers or compound heterozygotes with another pathogenic MEFV allele: colchicine is the standard of care, initiated as early as diagnosis. The standard prophylactic dose in adults is 0.5–2 mg/day adjusted to attack frequency. V726A genotype predicts a favorable response — most patients achieve full attack suppression at moderate doses. The primary rationale for strict prophylaxis is preventing AA amyloidosis, which requires sustained subclinical inflammation to accumulate serum amyloid A protein in the kidneys. Uncontrolled FMF — even without obvious fever attacks — elevates SAA levels and drives amyloidosis over years to decades. Colchicine normalizes inter-attack SAA in the majority of V726A-genotype patients.

Monitoring should include periodic urinalysis for proteinuria (screening for early renal amyloidosis) and serum SAA measurement to confirm inter-attack inflammatory suppression.

Interactions

V726A interacts meaningfully with other MEFV variants. Compound heterozygosity with M694V (rs61752717) elevates phenotype severity significantly above V726A homozygosity — Majeed et al. classified M694V/V726A as a "severe" genotype, comparable to M694V/M694V in clinical impact. V726A also participates in the complex allele V726A+E148Q (rs3743930), where both mutations sit on the same chromosome: this cis-combination is more severe than V726A alone, suggesting E148Q modifies pyrin function even in a trans-exon context.

For compound heterozygotes with M680I (rs61752720), disease is typically moderate — less severe than M694V/V726A but more active than V726A homozygosity alone. The specific compound genotype determines colchicine dose requirements and the urgency of prophylaxis.

The rs2943634 variant sits in an intergenic region of chromosome 2q36.3, approximately 528 kilobases upstream of the IRS1 gene¹¹ IRS1 gene
insulin receptor substrate 1, a central adaptor protein in insulin and IGF-1 signaling. Despite lying outside any protein-coding sequence, rs2943634 was independently replicated in genome-wide association studies for coronary artery disease²² genome-wide association studies for coronary artery disease
including the landmark Samani et al. 2007 NEJM GWAS and has since been shown to have a broader cardiovascular footprint including ischemic stroke, HDL cholesterol, and adiponectin.

The Mechanism

The SNP does not change any protein sequence. Instead, it likely acts as a regulatory variant³³ regulatory variant
altering gene expression of nearby genes through enhancer elements or chromatin remodeling. The nearest candidate gene is IRS1, encoding a key scaffold protein that transmits insulin and IGF-1 receptor signals to downstream metabolic pathways including PI3K-Akt and MAPK. IRS1 activity influences adiponectin secretion by adipocytes⁴⁴ adiponectin secretion by adipocytes
a cardioprotective adipokine that enhances insulin sensitivity, suppresses endothelial inflammation, and promotes reverse cholesterol transport.

The A allele is associated with higher circulating adiponectin and HDL cholesterol in an additive, dose-dependent manner. Crucially, when Arregui et al. adjusted for both adiponectin and HDL simultaneously⁵⁵ Arregui et al. adjusted for both adiponectin and HDL simultaneously
in mediation analyses within the EPIC-Potsdam cohort, the stroke association persisted, suggesting the variant also engages independent protective mechanisms beyond these two biomarkers.

The Evidence

The 2q36.3 locus was first tagged in the Samani et al. 2007 NEJM genome-wide association study⁶⁶ Samani et al. 2007 NEJM genome-wide association study
a joint analysis of the Wellcome Trust Case Control Consortium and the German MI Family Study, achieving genome-wide significance for coronary artery disease in European populations. The Coronary Artery Disease Consortium 2009⁷⁷ Coronary Artery Disease Consortium 2009
a large-scale multicenter replication study confirmed the locus in independent cohorts.

The most detailed functional analysis came from Arregui et al. 2012⁸⁸ Arregui et al. 2012
a nested case-cohort within the EPIC-Potsdam prospective study of 27,548 middle-aged German adults followed for a mean 8.2 years. The A allele was associated with [a 34% reduction in ischemic stroke risk | HR=0.66, 95% CI 0.50-0.87, P=0.003] in an additive model, while showing no significant association with myocardial infarction (HR=1.02, P=0.83). Adiponectin concentrations rose stepwise: CC 6.94, CA 7.27, AA 7.86 μg/ml (P=0.0002). HDL cholesterol followed the same pattern: CC 52.1, CA 53.1, AA 55.3 mg/dl (P=0.002).

In a broader cardiovascular context, the MORGAM prospective cohort study across N=33,282 participants⁹⁹ MORGAM prospective cohort study across N=33,282 participants
spanning multiple European countries, with 571 incident stroke events also linked rs2943634 to HDL cholesterol and blood pressure. The Dlouha et al. 2025 study in heart transplant recipients¹⁰¹⁰ Dlouha et al. 2025 study in heart transplant recipients
examining accelerated coronary disease post-transplant found the C allele associated with OR 2.46 (95% CI 1.12-6.17) for early cardiac allograft vasculopathy, an accelerated form of CAD that develops uniquely in transplanted hearts.

A 2012 metabolic syndrome study van der Valk et al. in EPIC-NL (N=1,886)¹¹¹¹ van der Valk et al. in EPIC-NL (N=1,886)
testing IRS1 locus variants and metabolic syndrome components found the A allele associated with OR 0.88 (95% CI 0.79-0.97) protection against metabolic syndrome, with significant associations across HDL, triglycerides, and HbA1c.

The evidence is replicated across European cohorts but inconsistently in some smaller studies — the strongest and most consistent signal is for ischemic stroke and HDL cholesterol. Effect sizes are modest (common variant with population-attributable effects), fitting the polygenic architecture of cardiovascular disease.

Practical Implications

Carrying one or two C alleles does not determine your fate — this is one of many common variants that collectively elevate cardiovascular risk. The clinical relevance lies in recognizing that [this genotype lowers circulating adiponectin and HDL | both biomarkers with direct anti-atherogenic and anti-inflammatory effects on the vascular wall]. People with the CC genotype may need to work harder to achieve the same HDL levels as AA carriers, and should be more proactive about monitoring vascular risk factors.

Interactions

rs2943634 co-occurs with other cardiovascular GWAS loci. The chromosome 9p21.3 locus (rs10757274)¹²¹² chromosome 9p21.3 locus (rs10757274)
one of the strongest genetic risk factors for coronary artery disease, near CDKN2A/B was studied alongside rs2943634 in the cardiac transplant study, and the two loci appeared to have additive effects on early allograft vasculopathy. The 6q25.1 locus (rs6922269)¹³¹³ 6q25.1 locus (rs6922269)
an MRAS gene variant associated with CAD has also been grouped with rs2943634 in multi-locus cardiovascular risk studies.

KCTD15 (Potassium Channel Tetramerization Domain-Containing 15) was identified as an obesity-associated gene through large-scale genome-wide association studies. The rs29941 variant sits in an intergenic region on chromosome 19 near KCTD15, and the G allele has been consistently associated with modestly increased BMI and obesity risk across multiple populations.

The Mechanism

KCTD15 is a member of the KCTD protein family that shares a common BTB domain¹¹ BTB domain
Bric-a-brac, Tramtrack, Broad complex domain — a protein-protein interaction motif at its N-terminal. The protein acts as a potent inhibitor of AP-2 transcription factors²² AP-2 transcription factors
Activating Protein 2, critical regulators of neural crest development and adipocyte differentiation. By binding directly to the activation domain of AP-2alpha, KCTD15 blocks its function in the neural crest induction hierarchy and in adipogenesis pathways.

AP-2alpha regulates the activity of C/EBPalpha³³ C/EBPalpha
CCAAT/enhancer-binding protein alpha, a master regulator of fat cell differentiation during adipogenesis. KCTD15 also interacts with GRP78⁴⁴ GRP78
glucose-regulated protein 78, an endoplasmic reticulum chaperone essential for adipogenesis across all phases of fat cell differentiation. Reduced KCTD15 activity may therefore promote excess adipogenesis and fat accumulation.

Additionally, KCTD15 attenuates the Wnt/beta-catenin signaling pathway⁵⁵ Wnt/beta-catenin signaling pathway
a key developmental pathway that also regulates adipocyte precursor commitment, further connecting it to fat tissue development.

The Evidence

The GIANT consortium meta-analysis⁶⁶ GIANT consortium meta-analysis
Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009 of more than 32,000 individuals first identified KCTD15 as a genome-wide significant BMI locus (P < 5 x 10^-8). This was confirmed in an expanded analysis of 249,796 individuals⁷⁷ expanded analysis of 249,796 individuals
Speliotes et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010.

In a study of 18,014 middle-aged Danes⁸⁸ study of 18,014 middle-aged Danes
Haupt et al. Studies of metabolic phenotypic correlates of 15 obesity associated gene variants. PLoS ONE, 2011, the G allele at rs29941 was associated with per-allele odds ratios of 1.15-1.20 for overweight and 1.41-1.46 for morbid obesity. The per-allele effect on BMI is approximately 0.06-0.07 kg/m² — modest individually but meaningful in combination with other obesity variants.

The association has been replicated in East Asian populations⁹⁹ replicated in East Asian populations
Ng et al. Implication of genetic variants near obesity loci with obesity and type 2 diabetes in 7,705 Chinese. J Clin Endocrinol Metab, 2010, though allele frequencies differ substantially (G allele: ~82% in Africans, ~68% in Europeans, ~24% in East Asians).

Practical Actions

As a common GWAS hit with a modest per-allele effect, this variant represents one piece of a larger genetic obesity risk profile. Carriers of the GG genotype should focus on strategies that specifically counter enhanced adipogenesis — targeting pathways that limit new fat cell formation rather than relying on generic advice.

Interactions

KCTD15 rs29941 contributes to polygenic obesity risk alongside FTO rs9939609, MC4R rs17782313, MTCH2 rs10838738, and ETV5 rs7647305. Genetic risk score analyses show that carrying risk alleles at multiple loci has a cumulative effect on BMI — individuals in the top decile of combined risk carry approximately 2-3 kg/m² higher BMI than those in the bottom decile. The KCTD15 adipogenesis pathway is mechanistically distinct from the FTO thermogenesis and MC4R appetite-regulation pathways, meaning their effects compound rather than overlap.

CTLA-4 (Cytotoxic T-Lymphocyte Associated protein 4) is a critical immune checkpoint molecule¹¹ molecule
CTLA-4 is expressed on activated T cells and functions as a negative regulator, preventing overactive immune responses that acts as a brake on the immune system. The CT60 variant (rs3087243), located in the 3' untranslated region of the CTLA4 gene²² of the CTLA4 gene
The 3'UTR region contains regulatory sequences that control mRNA stability and translation efficiency, is one of the most extensively studied autoimmune susceptibility variants. This single nucleotide change from A to G has profound implications for immune regulation and autoimmune disease risk.

The Mechanism

The CT60 variant sits in the 3'UTR of the CTLA4 mRNA, a region that doesn't code for protein but critically controls gene expression. The G allele is in strong linkage disequilibrium with an (AT)n dinucleotide repeat³³ with an (AT)n dinucleotide repeat
Longer (AT)n repeats are associated with the G allele and reduce CTLA4 mRNA stability in the same region. Research has shown that the length of this repeat inversely correlates with both CTLA4 mRNA and protein levels in autoreactive T-cell lines. When T cells carry longer (AT)n repeats linked to the G allele, they produce less CTLA-4 protein — the molecular brake on immune activation becomes weaker.

The 3'UTR sequence affects both mRNA stability and translational efficiency⁴⁴ The 3'UTR sequence affects both mRNA stability and translational efficiency
Studies using reporter gene assays demonstrated that the CTLA4 3'UTR can confer instability to mRNA and reduce protein expression in vitro. Additionally, the variant influences the ratio of full-length CTLA-4 (bound to cell membranes) to soluble CTLA-4 (circulating in blood), with the GG genotype associated with lower production of the soluble immunoregulatory form.

The Evidence

The association between rs3087243 and autoimmune disease is supported by extensive research across multiple conditions:

Graves' Disease and Autoimmune Thyroid Disease: A case-control study of 288 Graves' disease patients⁵⁵ case-control study of 288 Graves' disease patients
The G/G genotype frequency was 70.1% in cases vs 51.4% in controls found the GG genotype conferred an odds ratio of 2.22 (95% CI: 1.58-3.13) for disease. A comprehensive meta-analysis of 20 studies⁶⁶ comprehensive meta-analysis of 20 studies
Analysis included both Graves' disease and Hashimoto's thyroiditis across Asian and Caucasian populations confirmed that CT60 polymorphism confers susceptibility to autoimmune thyroid diseases, with the G allele consistently associated with increased risk across ethnicities.

Type 1 Diabetes: The variant's role in type 1 diabetes is particularly notable in individuals who also develop thyroid autoimmunity. In a study of 4,364 type 1 diabetic patients⁷⁷ study of 4,364 type 1 diabetic patients
10.6% had thyroid peroxidase autoantibodies (TPOAbs), those with TPOAbs showed a significantly stronger association with rs3087243 (OR = 1.49 for G allele) compared to TPOAbs-negative patients (OR = 1.16). This subgroup also had a 1.94:1 female-to-male ratio compared to 0.94:1 in those without thyroid autoimmunity.

Latent Autoimmune Diabetes in Adults (LADA): A meta-analysis of 820 LADA cases⁸⁸ meta-analysis of 820 LADA cases
Analysis included 4,824 controls across multiple ethnic groups identified significant associations with LADA, particularly in Caucasian populations under a recessive model, suggesting two copies of the risk allele substantially increase susceptibility.

Rheumatoid Arthritis: A large meta-analysis of 66 studies⁹⁹ large meta-analysis of 66 studies
Included 21,681 RA patients and 23,457 controls found that A allele carriers had approximately 13% reduced risk compared to G allele carriers, with the AA genotype showing 20% reduced risk compared to GG. This means the G allele is also the risk allele for RA, consistent with its role in other autoimmune conditions, though the effect size is smaller than for thyroid disease.

Practical Implications

If you carry one or two G alleles at rs3087243, your immune system's "off switch" may be less effective. This doesn't mean you'll develop autoimmune disease — most carriers never do — but it does mean your T cells are more prone to activation and potentially more likely to attack your own tissues under the right (or wrong) environmental triggers.

The clinical significance varies by which autoimmune conditions run in your family. If you have relatives with thyroid disease, type 1 diabetes, or other autoimmune conditions, the G allele may be particularly relevant to monitor. Women with the GG genotype who also have type 1 diabetes should be especially vigilant about thyroid function, as this combination strongly predisposes to autoimmune thyroid disease.

For those with established autoimmune conditions, understanding your CTLA4 genotype may eventually inform treatment decisions. CTLA-4 is the target of checkpoint inhibitor immunotherapies¹⁰¹⁰ CTLA-4 is the target of checkpoint inhibitor immunotherapies
Drugs like ipilimumab block CTLA-4 to enhance immune responses against cancer used in cancer treatment, and genetic variation at this locus may predict both therapeutic response and immune-related adverse events.

Interactions

CTLA4 rs3087243 interacts with other immune-regulatory variants to modulate autoimmune risk. The most notable interaction is with rs231775 (+49A/G)¹¹¹¹ rs231775 (+49A/G)
This exon 1 variant causes a threonine-to-alanine amino acid change affecting CTLA-4 glycosylation, also in the CTLA4 gene, which affects CTLA-4 protein folding and cell surface expression. Individuals carrying risk alleles at both positions show enhanced susceptibility to Graves' disease and type 1 diabetes compared to either variant alone.

The variant also shows epistatic interactions with PTPN22 rs2476601 (another T-cell regulatory gene variant) in determining autoimmune disease risk. Evidence suggests genetic interaction between HLA class II genotypes and rs3087243 in type 1 diabetes¹²¹² Evidence suggests genetic interaction between HLA class II genotypes and rs3087243 in type 1 diabetes
Combined effects were observed beyond simple additive models, indicating that autoimmune susceptibility emerges from complex networks of immune gene variants rather than single mutations.

Vitamin C cannot be made by the human body. Every microgram of ascorbate¹¹ ascorbate
The biologically active, ionized form of ascorbic acid at physiological pH in your blood got there by being eaten and then actively transported across your intestinal lining and conserved by your kidneys. The gene SLC23A1 encodes SVCT1²² SVCT1
Sodium-dependent Vitamin C Transporter 1 — a 12-transmembrane-domain protein expressed on the apical surface of intestinal and kidney epithelial cells, the transporter protein responsible for both of these steps. A single nucleotide change at position 264 swaps valine for methionine in the transporter, reducing its efficiency and measurably lowering circulating vitamin C levels.

The Mechanism

SVCT1 is an apical membrane³³ apical membrane
The cell surface facing the intestinal lumen or kidney tubule, where nutrients are absorbed from transporter that uses the sodium gradient to drive ascorbic acid into intestinal epithelial cells and kidney tubule cells. In the intestine it mediates dietary vitamin C absorption; in the kidney it reclaims filtered ascorbate before it can be lost in urine. The Val264Met substitution occurs in the protein's core transmembrane region, likely altering the conformational changes needed for the transport cycle. In vitro studies show the variant transporter moves ascorbate at roughly 40-50% reduced capacity⁴⁴ 40-50% reduced capacity
Eck P et al. Genomic and functional analysis of the sodium-dependent vitamin C transporter SLC23A1-SVCT1. Genes Nutr, 2007 compared to the wild-type protein.

Knockout mouse studies⁵⁵ Knockout mouse studies
Corpe CP et al. Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest, 2010 dramatically illustrate SVCT1's importance: mice completely lacking Slc23a1 excrete 18 times more ascorbate in their urine, and 45% of pups die perinatally from vitamin C depletion. Humans carrying Val264Met have a far milder effect — they still absorb and reabsorb vitamin C, just less efficiently.

The Evidence

The definitive human study is a meta-analysis of five independent UK cohorts⁶⁶ meta-analysis of five independent UK cohorts
Timpson NJ et al. Genetic variation at the SLC23A1 locus is associated with circulating concentrations of L-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participants. Am J Clin Nutr, 2010 totaling 15,087 participants. Each copy of the T allele was associated with a 5.98 umol/L reduction in plasma vitamin C (95% CI: -8.23 to -3.73; P = 2.0 x 10^-7). Heterozygotes had roughly 24% lower plasma vitamin C than homozygous normal individuals. The effect was consistent across all five cohorts, ranging from -4.15 umol/L in the discovery cohort to -8.31 umol/L in the EPIC-Norfolk study.

For context, adequate plasma vitamin C is generally considered to be above 28 umol/L, with levels below 11 umol/L indicating deficiency. A reduction of ~6 umol/L per allele is clinically meaningful in people whose dietary intake is already marginal — it can push borderline-adequate levels into the insufficient range.

The variant has also been used as a genetic instrument in Mendelian randomization studies⁷⁷ Mendelian randomization studies
Wade KH et al. Variation in the SLC23A1 gene does not influence cardiometabolic outcomes to the extent expected given its association with L-ascorbic acid. Am J Clin Nutr, 2015 to test whether vitamin C causally protects against cardiovascular disease. Despite strong observational correlations between higher vitamin C and better cardiometabolic profiles, the genetic evidence showed no causal relationship — the observational associations are likely due to confounding (people who eat more fruit and vegetables tend to be healthier overall). A similar Mendelian randomization in 106,147 individuals⁸⁸ 106,147 individuals
Kobylecki CJ et al. Genetically high plasma vitamin C and urate: a Mendelian randomization study. Rheumatology, 2018 found no causal link between genetically determined vitamin C levels and plasma urate or gout risk.

Practical Implications

The Val264Met variant is relatively rare — only about 3-4% of Europeans carry one copy, and homozygotes are extremely uncommon (<0.5%). Among people of African descent the T allele is somewhat more common (~6%), while it is rarer in East Asian (~1.2%) and South Asian (~1.5%) populations.

For carriers, the key takeaway is straightforward: your body is less efficient at absorbing and retaining vitamin C, so you may need to be more intentional about intake. This does not mean megadosing — vitamin C absorption has a saturation ceiling regardless of genotype. It means ensuring you consistently get enough through diet (citrus, berries, bell peppers, broccoli, kiwi) or a modest daily supplement (200-500 mg ascorbic acid), and being aware that your baseline plasma levels will run lower than someone with the same diet but normal SVCT1 function.

Smokers and people with high oxidative stress should pay particular attention, since smoking independently lowers vitamin C levels. If you carry this variant and smoke, or have a diet low in fruits and vegetables, your plasma ascorbate may dip into the deficiency range.

Interactions

SLC23A1 works alongside SLC23A2⁹⁹ SLC23A2
Encodes SVCT2, a vitamin C transporter expressed in metabolically active tissues (brain, adrenals, eyes). Unlike SVCT1, which controls whole-body homeostasis, SVCT2 handles local tissue-level vitamin C delivery, which encodes the tissue-level vitamin C transporter SVCT2. Variants in both transporters could theoretically compound the effect on vitamin C status, though this specific interaction has not been well studied. In the EPIC cohort, both rs33972313 (SLC23A1) and SLC23A2 variants (rs6053005, rs6133175) independently predicted plasma vitamin C levels, suggesting additive effects on vitamin C homeostasis.

TRAF3IP2 encodes Act1 (also called CIKS — connector of kinase to stress-activated protein kinase), the essential adaptor protein¹¹ essential adaptor protein
Act1 is recruited to the cytoplasmic domain of the IL-17 receptor complex upon IL-17A or IL-17F binding that bridges IL-17 receptor activation to downstream inflammatory gene expression. When IL-17 binds its receptor on keratinocytes, fibroblasts, and mucosal epithelial cells, Act1 assembles a signaling scaffold that recruits TRAF6 and ultimately activates NF-κB — the master switch for pro-inflammatory cytokines including IL-6, IL-8, CXCL1, and GM-CSF. The D10N variant disrupts this scaffold at its very foundation, producing consequences that are paradoxical and clinically important.

The Mechanism

Aspartic acid at position 10 of Act1 is required for two critical interactions: binding to the molecular chaperone Hsp90²² binding to the molecular chaperone Hsp90
Act1 is an obligate client protein of Hsp90; the chaperone stabilizes Act1 and directs its proper folding and activity, and binding to TRAF6, TRAF2, and TRAF3. The D10N substitution (aspartic acid → asparagine, a conservative but chemically critical change) abolishes both interactions simultaneously.

Without Hsp90 regulation, D10N Act1 loses its ability to engage any known IL-17 signaling component³³ D10N Act1 loses its ability to engage any known IL-17 signaling component
D10N-reconstituted Act1-deficient cells fail to activate IκBα phosphorylation, Erk/Jnk, or NF-κB upon IL-17 stimulation — it cannot bind IL-17 receptor, TRAF6, TRAF2, TRAF3, or IKKi. Functional assays demonstrated near-complete disruption of TRAF6 binding⁴⁴ near-complete disruption of TRAF6 binding
Full-length TRAF3IP2 construct containing D10N showed a nearly completely disrupted interaction with TRAF6 compared to wild-type Act1, making it effectively a loss-of-function allele in the IL-17 pathway.

The paradox: losing IL-17 signaling through Act1 should dampen inflammation. Instead, Act1-null mice develop spontaneous skin inflammation driven by IL-22⁵⁵ Act1-null mice develop spontaneous skin inflammation driven by IL-22
In the absence of IL-17-mediated signaling, IL-22 becomes the dominant inflammatory cytokine and T-cell-intrinsic Act1 loss causes hyper-Th17 responses. IL-17 signaling normally provides a negative feedback on Th17 cell expansion. When Act1 is non-functional, this brake is removed, Th17 cells proliferate excessively, and IL-22-driven keratinocyte hyperproliferation — the hallmark of psoriatic plaques — ensues.

The Evidence

Two independent genome-wide association studies published simultaneously in 2010 established TRAF3IP2 as a major psoriasis susceptibility locus. The coding variant rs33980500 showed combined P=1.13×10⁻²⁰ with OR=1.95⁶⁶ combined P=1.13×10⁻²⁰ with OR=1.95
Discovery cohort of 609 German PsA cases plus replication in 6 European cohorts totaling 5,488 individuals — one of the strongest non-HLA associations in psoriasis genetics. A concurrent GWAS⁷⁷ concurrent GWAS
Independent US/Canadian cohort with 6,487 cases and 8,037 controls, combined P=1.24×10⁻¹⁶ confirmed the association, with OR for psoriatic arthritis reaching 1.57 (95% CI 1.38–1.78).

The T risk allele shows marked ancestry stratification⁸⁸ marked ancestry stratification
Variant absent in Han Chinese; frequency ~7.4% European, ~14.2% African, ~1.1% East Asian: common in European and African populations but nearly absent in East Asian populations, where psoriasis has a different genetic architecture. This population difference explains why TRAF3IP2 associations were discovered in European cohorts.

Neutrophil extracellular traps (NETs) — DNA-protein webs released by activated neutrophils⁹⁹ Neutrophil extracellular traps (NETs) — DNA-protein webs released by activated neutrophils
NETs are abundant in psoriatic lesions and known to trigger Th17 differentiation via TLR2 and TLR4 activation interact with D10N genotype in a dose-dependent manner: in the presence of spontaneous NETs, both Th17 percentages and IL-17A release were significantly more pronounced in D10N homozygotes than wild-type, linking innate immune triggers specifically to the D10N genotype.

Practical Implications

The D10N variant has two clinical dimensions: disease susceptibility and treatment pharmacogenomics.

For disease risk, T allele carriers have 1.3-fold (heterozygous) to 1.95-fold (homozygous) elevated baseline risk for psoriasis vulgaris and psoriatic arthritis. The variant predisposes to the IL-22-driven keratinocyte proliferation and plaque formation characteristic of psoriasis. Psoriasis triggers — skin trauma (Koebner phenomenon), streptococcal infections, certain medications (beta-blockers, lithium, antimalarials), and obesity — are especially relevant for T allele carriers.

For anti-IL-17 biologic therapy (secukinumab, ixekizumab, brodalumab), the D10N variant has pharmacogenomic significance. Because these drugs block IL-17A or the IL-17 receptor, and because D10N carriers already have impaired IL-17 downstream signaling, the therapeutic pathway is partially pre-disrupted. One pharmacogenomic analysis found that TRAF3IP2_v1 allele absence was associated with better secukinumab response¹⁰¹⁰ TRAF3IP2_v1 allele absence was associated with better secukinumab response
HLA-Cw6+ patients responded significantly better to secukinumab depending on TRAF3IP2_v1 allele absence in HLA-Cw6+ patients. For TNF-inhibitor therapy¹¹¹¹ TNF-inhibitor therapy
163 PsA patients; TRAF3IP2 variant allele carriers showed better DAPsA score improvement on TNF-inhibitors at 22 and 54 weeks, suggesting the variant modifies biologic treatment response, D10N carriers showed improved joint inflammation outcomes.

Psoriatic skin, when present, should be evaluated for joint involvement (psoriatic arthritis affects ~30% of psoriasis patients); early detection matters because joint damage is progressive.

Interactions

The TRAF3IP2 D10N variant operates within the broader IL-17/Th17 pathway where multiple genetic loci converge. rs12191877 (HLA-C*06:02), the strongest psoriasis susceptibility variant, primarily affects T-cell recognition of self-antigens and is the main predictor of biologic response (especially ustekinumab). The combination of HLA-C*06:02 with TRAF3IP2 D10N creates a dual-hit: impaired immune tolerance (HLA) plus enhanced Th17 expansion with IL-22 skew (TRAF3IP2).

rs12188300 (IL12B) affects upstream Th17 differentiation through IL-12/IL-23 signaling. IL-23 drives Th17 commitment; when TRAF3IP2 D10N then removes the IL-17-dependent negative feedback on Th17 cells, the combination of enhanced Th17 differentiation (IL12B) and unregulated Th17 expansion (TRAF3IP2) may substantially amplify psoriasis susceptibility and plaque severity.

A compound action examining the interaction between rs33980500-T and rs12191877-T (HLA-C*06:02) would be appropriate: both genotypes should co-occur in the same individual for consideration of early dermatology referral and monitoring for biologic therapy eligibility, given substantially elevated combined psoriasis risk and pharmacogenomically relevant anti-IL-17 response modification.

The lymphotoxin beta receptor (LTBR)¹¹ lymphotoxin beta receptor (LTBR)
A member of the TNF receptor superfamily encoded on chromosome 12p13.31; binds lymphotoxin-α1β2 and the LIGHT cytokine is a critical organizer of secondary lymphoid tissue architecture and innate immune tone. rs3758524 is a regulatory intronic variant associated with altered LTBR expression. Carriers of the minor A allele may have reduced LTBR signaling output — a change with consequences for how the immune system organizes lymphoid structures and mounts defenses against intracellular pathogens.

The A allele is rare across all populations, occurring in roughly 1–5% of individuals globally, with higher frequencies observed in East Asian populations (approximately 2–5%) compared to Europeans (~1%) or Africans (~1%). Most people carry the common GG genotype.

The Mechanism

LTBR sits at the hub of a dual NF-κB signaling network. When bound by its ligands, LTBR engages the classical IKKβ/IKKγ complex²² When bound by its ligands, LTBR engages the classical IKKβ/IKKγ complex
This leads to rapid degradation of IκBα and transient activation of RelA:p50 dimers, producing an acute inflammatory response. In parallel, LTBR triggers the alternative (non-canonical) NF-κB pathway³³ alternative (non-canonical) NF-κB pathway
This pathway uses NIK (NF-κB-inducing kinase) and IKKα to process p100 into p52, generating sustained RelB:p52 complexes that drive lymphoid organogenic genes. These two pathways operate independently and are not redundant — together, they shape chemokine gradients, follicular dendritic cell maturation, and stromal cell function in lymph nodes and spleen.

Regulatory variants that reduce LTBR expression dampen both arms of this response⁴⁴ Regulatory variants that reduce LTBR expression dampen both arms of this response
Reduced surface receptor density means less signal transduction per ligand-binding event, blunting both the acute RelA response and the sustained RelB organogenic response. The net effect is subtly impaired lymphoid tissue organization and reduced innate capacity to respond to certain pathogens.

The Evidence

LTBR's role in infection defense is most directly established in mycobacterial models. Blocking LTβR signaling in mice infected with Mycobacterium bovis BCG impaired granuloma formation in the spleen, suppressed macrophage activation, reduced nitric oxide synthase activity, and shifted immune responses from Th1 (IFN-γ) to Th2 (IL-4)⁵⁵ Blocking LTβR signaling in mice infected with Mycobacterium bovis BCG impaired granuloma formation in the spleen, suppressed macrophage activation, reduced nitric oxide synthase activity, and shifted immune responses from Th1 (IFN-γ) to Th2 (IL-4)
A soluble LTβR-IgG1 fusion protein was used to block signaling. Critically, the LTBR and TNF receptor pathways are non-redundant⁶⁶ non-redundant
Blocking both simultaneously caused extensive splenic necrosis — neither compensates for the other.

For the specific rsid, direct human genetic association data is limited. However, the broader LTBR variant literature provides biological grounding. A study of LTBR rs12354 in hepatitis B found that the T allele was significantly enriched in HBV spontaneous resolvers⁷⁷ A study of LTBR rs12354 in hepatitis B found that the T allele was significantly enriched in HBV spontaneous resolvers
GT genotype: 38.4% in resolvers vs 22.2% in chronically infected patients (p = 0.004), suggesting that genetic differences in LTBR function modulate viral infection outcomes. LTBR promoter variants (rs3759334 and rs2364480) were associated with IgA nephropathy in Korean children⁸⁸ LTBR promoter variants (rs3759334 and rs2364480) were associated with IgA nephropathy in Korean children
rs3759334 dominant model p = 0.017; rs2364480 allele p = 0.041, implicating LTBR in immune-complex-mediated inflammatory disease susceptibility.

In the context of juvenile idiopathic arthritis and systemic sclerosis, LTBR pathway activity influences tertiary lymphoid structure (TLS) formation at inflamed joints and fibrotic tissues — a mechanism under active investigation. The evidence base for rs3758524 specifically is emerging, with no large-scale genetic association studies published to date.

Practical Implications

Carriers of the A allele face a modestly altered baseline of LTBR-mediated immune signaling. The main practical concerns are in two areas: susceptibility to certain intracellular pathogens that rely on granuloma-mediated containment, and potentially altered risk of inflammatory conditions where tertiary lymphoid structures shape disease chronicity. Given the rarity of the A allele and the emerging state of the evidence, the actionable focus is on monitoring and early intervention for infections rather than any specific preventive supplement or avoidance.

Interactions

LTBR signaling interacts functionally with the TNF receptor pathway (TNFR1/TNFR2), and these pathways show additive rather than redundant effects in controlling intracellular infections. LTBR-driven alternative NF-κB also intersects with LIGHT/HVEM signaling (TNFRSF14, rs1886730), which shares ligands and downstream targets. Variants in the classical NF-κB arm (RELA, NFKB1) could modulate how much compensation occurs when LTBR signaling is reduced.